Processa Pharmaceuticals
PCSA
16 hedge funds and large institutions have $11.2M invested in Processa Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
23% more funds holding
Funds holding: 13 → 16 (+3)
0% more ownership
Funds ownership: 0.01% → 0.02% (+0%)
9% less capital invested
Capital invested by funds: $12.3M → $11.2M (-$1.07M)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.67M |
| 2 |
BlackRock
New York
|
+$213K |
| 3 |
State Street
Boston,
Massachusetts
|
+$128K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$73.4K |
| 5 |
CBA
Coastal Bridge Advisors
Westport,
Connecticut
|
+$58K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$309K |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$115K |
| 3 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$54.1K |
| 4 |
SCM
Solas Capital Management
Darien,
Connecticut
|
-$30.9K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$23.2K |
PCSA Hedge Fund Activity: Q2 2021 in Review
16 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Processa Pharmaceuticals (PCSA) for Q2 2021, worth a combined $11.2M — down 8.7% from $12.3M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PCSA positions and 1 closed out — a net gain of 3 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.67M. The largest seller was Millennium Management, cutting an estimated $309K.
- 16 institutional investors held Processa Pharmaceuticals (PCSA) as of Q2 2021, up from 13 in Q1 2021.
- Funds reported $11.2M of Processa Pharmaceuticals stock for Q2 2021, down 8.7% quarter-over-quarter.
- 4 funds opened new Processa Pharmaceuticals positions in Q2 2021 and 1 closed out, a net change of +3 holders.
- The largest Processa Pharmaceuticals buyer in Q2 2021 was Vanguard Group, an estimated $1.67M added.
- The largest Processa Pharmaceuticals seller in Q2 2021 was Millennium Management, an estimated $309K sold.
Based on aggregated 13F filings for Q2 2021.